Machina Capital S.A.S. Sells 5,255 Shares of IQVIA Holdings Inc. $IQV

Machina Capital S.A.S. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 73.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,859 shares of the medical research company’s stock after selling 5,255 shares during the period. Machina Capital S.A.S.’s holdings in IQVIA were worth $293,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. grew its holdings in shares of IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after purchasing an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA in the first quarter worth approximately $77,096,000. Finally, Nuveen LLC bought a new position in shares of IQVIA in the first quarter worth approximately $76,328,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock opened at $211.20 on Wednesday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $35.97 billion, a P/E ratio of 28.97, a P/E/G ratio of 2.39 and a beta of 1.34. The business has a fifty day simple moving average of $198.10 and a two-hundred day simple moving average of $175.09. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IQV. Citigroup raised their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and raised their price target for the stock from $206.00 to $215.00 in a research note on Monday. HSBC raised IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Finally, Barclays boosted their price target on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.94.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.